What does BPC-157 TB-500 do in research?

In published studies, each peptide was tested on its own, mostly in rats and cell cultures. BPC-157 activated VEGFR2, a receptor that drives new blood vessel growth, and improved healing measures after rat Achilles tendons or knee ligaments were cut. Thymosin beta-4, the sequence sold as TB-500, binds actin and sped wound closure in a rat skin model, with more collagen and blood vessels than controls.

Researchers study the pair to see whether those two routes add up in one tissue repair model. No peer-reviewed study has tested the combination yet, and none of the data describe effects in people. Read our research purposes only policy, then view the specs for the Wolverine stack.